Skip to main content
. 2023 Mar 15;20(6):5129. doi: 10.3390/ijerph20065129
AIDS acquired immunodeficiency syndrome
CB1 and CB2 cannabinoid receptors type 1 and 2
CBD cannabidiol
CD Crohn’s disease
CYP cytochrome P
ECS endocannabinoid system
F female
FDA Food and Drug Administration (United States)
IBD inflammatory bowel disease
IRB Institutional review board
M male
PR Puerto Rico
THC tetrahydrocannabinol
UC ulcerative colitis
UK United Kingdom
US United States
USD United States dollars